Lamivudine

Specifications

134678-17-4CAS Number

603-844-3EC Number

4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-oneIUPAC Name

C8H11N3O3SChemical Formula

229.26 g/molMolecular Weight

lamivudine; 134678-17-4; Epivir; Zeffix; Epivir-HBV; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; (-)-2'-Deoxy-3'-thiacytidine; GR-109714X; VIROLAM; (-)-BCH-189; GR109714X; 3'-Thia-2',3'-dideoxycytidine; Lamivudine teva; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BCH 189, (-)-; Lamivudina; Lamivudinum; GR 109714X; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; BCH189; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; CHEBI:63577; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 2T8Q726O95; NSC-760061; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; TRIUMEQ COMPONENT LAMIVUDINE; LAMIVUDINE TEVA PHARMA B.V.; TRIZIVIR COMPONENT LAMIVUDINE; DELSTRIGO COMPONENT LAMIVUDINE; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE; DTXSID7023194; Epivir HBV; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; lamivudine oral; 3TC Lamivudine; 2',3' Dideoxy 3' thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-1,2-dihydropyrimidin-2-one; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2-one; Lamivudine, 3TC; RefChem:798426; J05AF05; DTXCID001508532; 603-844-3; Heptovir; 136891-12-8; 3TC; BCH-189; Heptodin; Lamivir; CIS-LAMIVUDINE; 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; (-)NGPB-21; MFCD00869739; Hepitec; Zefix; Heptivir; BCH 189; Lamivudine [USAN:BAN:INN]; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone,4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-; Epivir(TM); HHA & Lamivudine; Lamivudine & GNA; SMR000466319; Epivir (TN); (-)-BCH 189; DTHC; rac-cis-Lamivudine ((2RS,5SR)-Lamivudine); CHEMBL141; HSDB 7155; DRG-0126; GG-714; 3TC and NV-01; (-)-SddC; Lamivudeine; Lamivudine (JAN/USP/INN); 3TC & GNA; 3TC & SST; HHA & 3TC; (+/-)-SddC; CCRIS 9274; Lamivudine RS; NSC620753; Lamivudine CRS; Epivir;; UNII-2T8Q726O95; BCH-790; Lamivudine [USAN:USP:INN:BAN]; NCGC00159341-04; Lamivudine (Standard); Lamivudine (EPIVIR); CPD000466319; LAMIVUDINE [MI]; (+/-)-3TC; (+/-)-BCH-189; LAMIVUDINE [INN]; LAMIVUDINE [JAN]; LAMIVUDINE [HSDB]; LAMIVUDINE [USAN]; LAMIVUDINE [VANDF]; Epitope ID:613392; LAMIVUDINE [MART.]; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-; LAMIVUDINE [USP-RS]; LAMIVUDINE [WHO-DD]; LAMIVUDINE [WHO-IP]; Lamivudine, cis-(+/-)-; US4RZW252L; MLS000759424; MLS001424097; MLS006011910; BIDD:GT0033; LAMIVUDINE [EMA EPAR]; SCHEMBL109675; Lamivudine - Bio-X trade mark; orb1310390; orb3141279; LAMIVUDINE [EP IMPURITY]; LAMIVUDINE [ORANGE BOOK]; GTPL12673; HY-B0250R; LAMIVUDINE [EP MONOGRAPH]; KIVEXA COMPONENT LAMIVUDINE; GLXC-05058; HMS2051D21; HMS3259F08; HMS3713C16; LAMIVUDINE [USP MONOGRAPH]; EPZICOM COMPONENT LAMIVUDINE; LAMIVUDINUM [WHO-IP LATIN]; TEMIXYS COMPONENT LAMIVUDINE; ALBB-038661; COMBIVIR COMPONENT LAMIVUDINE; HY-B0250; MSK10170; Lamivudine for system suitability RS; BBL033871; BDBM50366817; EBC-03887; s1706; SBB066293; STK801940; lamivudine & TNF-alpha & IFN-gamma; AKOS005622556; AKOS015854841; Lamivudine, >=98% (HPLC), powder; (-)-BCH189; AC-1416; CCG-100984; DB00709; KS-1073; NC00234; NC00705; NL06295; NSC 760061; Lamivudine for system suitability 1 CRS; NCGC00159341-05; NCGC00159341-11; NCGC00159341-18; NCGC00159341-20; BL164607; EMTRICITABINE IMPURITY C [WHO-IP]; L0217; NS00007004; SW197614-3; C07065; D00353; EN300-123034; Lamivudeine 100 |Ig/mL in Acetonitrile:Water; Lamivudine 100 microg/mL in Acetonitrile:Water; P17147; AB00639995-06; AB00639995-08; AB00639995_09; F227713; Q422631; SR-01000759420; SR-01000759420-5; BRD-K02992638-001-11-8; Z1509637175; Lamivudine Working Standard (Secondary Reference Standard); Lamivudine, British Pharmacopoeia (BP) Reference Standard; Lamivudine, European Pharmacopoeia (EP) Reference Standard; (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; cis(+/-)-2-Hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane; Lamivudine, United States Pharmacopeia (USP) Reference Standard; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR; Lamivudine, 1.0 mg/mL in methanol, certified reference material; Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, cis-; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, cis-(+/-)-; 3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one; cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard; rel-4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 1117764-41-6; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA); 4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]Synonyms